Aurobindo Pharma
AUROPHARMA · Pharma > Pharmaceuticals & Drugs · Chairman: K Ragunathan · MD: N Govindarajan · Listing date: June 14, 1995 · Employees: 19364 · Hyderabad · http://www.aurobindo.com

Stock Price vs Company Growth
1d
1.5%
1w
0.8%
1m
11.8%
3m
10.9%
6m
19.3%
1y
3.4%
5y
26.0%
10y
7.5%
all
17.3%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

1,176 1.5%
1,031
1,328
Company Overview

Sales
30,922 Cr
Growth: 10.7%
Profit after Tax
3,491 Cr
Growth: -2.5%
Large Cap
68,305 Cr
P/E: 19.7x
Industry P/E: 33.0x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 30,922
Growth 10.7%
EBITDA 20.8%
P/S 2.2x
Dividend 0.0%
P/E 19.7x
Book Value ₹ 558
PEG Ratio 1.8x
ROE 11.2%
P/B 2.1x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
3.46 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
3.4 %
Qualified Institutional Buyer
1.95 %
Nippon Life India Trustee Ltd-A/C Nippon India Pharma Fund
1.32 %
Bnp Paribas Arbitrage
1.22 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Dec22
Promoters
Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding)
33.51 %
K Nityananda Reddy
4.33 %
Kirthi Reddy Kambam
3.49 %
Venkata Ramprasad Reddy Penaka
3.07 %
Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd. (Jointly Holding)
2.85 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Dec22
Others
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep21Dec22
Increase    Decrease    No change
Company Profile Detailed

Aurobindo Pharma continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration.
Investors (197)
Followers (74)